Actualités et vidéos - VERTEX PHARMACEUTICALS INC.

VERTEX TREEFROG THERAPEUTICS CONCLUT UN ACCORD STRATEGIQUE ET DE LICENCE AVEC L'AMERICAIN VERTEX PHARMACEUTICALS POUR OPTIMISER LA PRODUCTION DE THERAPIES CELLULAIRES DANS LE DIABETE DE TYPE 1 PR Newswire BOSTON and BORDEAUX, France, 23 avril 2024 TreeFrog accorde à Vertex une licence mondiale de sa technologie de fabrication C-Stem TM dans le diabète de type 1 Les deux sociétés visent la mise à l'échelle de cellules d'îlots pancréatiques différenciées et productrices d'insuline BOSTON...

Thinking about trading options or stock in Tesla, Energy Transfer, Paramount Global, Vertex Pharmaceuticals, or Broadcom ? PR Newswire NEW YORK, March 21, 2024 NEW YORK , March 21, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TSLA, ET, PARA, VRTX, and AVGO. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all...

Whittier's Annual Roast to Toast Fundraiser on April 3rd, 2024 Will Support Health and Social Services for Boston's Most Vulnerable Residents BOSTON, MA / ACCESSWIRE / March 11, 2024 / Whittier's 2024 "Toast of Jeffrey Leiden" will continue the health center's long tradition of shining a light on Boston's standout business leaders and philanthropists while raising critical funds to provide high-quality medical care and social services to patients regardless of their ability to pay for services....

Thinking about buying stock in Chenghe Acquisition, Vertex Pharmaceuticals, VinFast Auto, 4D Molecular Therapeutics, or MicroCloud Hologram? PR Newswire NEW YORK, Feb. 5, 2024 NEW YORK , Feb. 5, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHEA, VRTX, VFS, FDMT, and HOLO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CHEA:...

Thinking about buying stock in Safety Shot, Transcode Therapeutics, Vertex Pharmaceuticals, Spotify Technology, or Omega Therapeutics? PR Newswire NEW YORK, Jan. 18, 2024 NEW YORK , Jan. 18, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SHOT, RNAZ, VRTX, SPOT, and OMGA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. SHOT:...

Thinking about buying stock in Safe & Green Development, Esperion Therapeutics, Ford Motor, Vertex Pharmaceuticals, or LifeMD? PR Newswire NEW YORK, Jan. 5, 2024 NEW YORK , Jan. 5, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SGD, ESPR, F, VRTX, and LFMD. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. SGD:...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of preclinical data and the results from its Phase 2 proof-of-concept trials evaluating treatment with the selective, oral NaV1.8 inhibitor VX-548 for acute pain following abdominoplasty and bunionectomy surgeries. “VX-548 preclinical studies demonstrated high selectivity and potency for the NaV1.8 sodium channel which translated into Phase 2 clinical results with strong...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2023 and updated its full year 2023 financial guidance. “The second quarter of 2023 marked another period of strong progress across our business. We are reaching more patients globally with our cystic fibrosis medicines, advancing our late-stage clinical programs and making rapid progress across our research and development pipeline of transformative...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for the label extension of ORKAMBI ® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) ages 1 to <2 years old who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene, the most common form of the disease. “This approval will offer some of the youngest children with cystic fibrosis the chance of improved outcomes, by...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2023 financial results on Tuesday, August 1, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1(412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2023 Earnings Call.” The conference call will be webcast live and a link to the webcast can be accessed through...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented data on all patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). All six patients treated with VX-880 had undetectable fasting C-peptide (endogenous insulin secretion) at baseline, a history of recurrent SHEs in the...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 12 scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines were presented at this year’s European Cystic Fibrosis Society's (ECFS) 46th European Cystic Fibrosis Conference held June 7-10, 2023, in Vienna, Austria. Together, the data presented show the long-term benefits of treatment with CFTR modulators as well as the importance of treating the underlying cause of CF as early in life as...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary endpoints at pre-specified interim analyses. The results are being presented at the Annual European Hematology Association (EHA) Congress. “The updated results from both the TDT and SCD trials are...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Prescription Drug User Fee Act (PDUFA) target...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 44 th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, Chief Executive Officer and President, and Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat on Tuesday, June 13, 2023 at 2:40 p.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved KALYDECO ® (ivacaftor) for use in children with cystic fibrosis (CF) ages 1 month to less than four months old who have at least one mutation in their cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is responsive to KALYDECO ® based on clinical and/or in vitro assay data. KALYDECO ® is already approved in the U.S. and EU for the treatment of CF in...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2023 and reiterated full year 2023 financial guidance. “Vertex delivered a strong start to 2023, with outstanding execution across our business. We continue to reach more patients globally with our cystic fibrosis medicines and progress our broad and diverse pipeline, most notably completing the rolling BLA submissions for exa-cel in the U.S.,” said Reshma...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved the expanded use of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include children with cystic fibrosis (CF) ages 2 through 5 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene or a mutation in the CFTR gene that is responsive to TRIKAFTA ® based on in vitro data. TRIKAFTA ® was previously...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 9:20 a.m. PT/12:20 p.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the “Vertex Pharmaceuticals First Quarter 2023 Earnings Call.” The conference call will be webcast live and a link to the webcast can be accessed through...